NCT05751759View on ClinicalTrials.gov

Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

31

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

November 21, 2024

Study Completion Date

November 21, 2024

Conditions

Hepatic Impairment

Interventions

DRUG

Mitiperstat

Participants receive mitiperstat orally.

Trial Locations (5)

32808

Research Site, Orlando

33016

Research Site, Hialeah

44718

Research Site, Canton

78215

Research Site, San Antonio

92377

Research Site, Rialto

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY